2023 World Conference on Lung Cancer (Posters)-EP07.02. Prospective Study of Hypofractionated Proton Therapy for Inoperable Early Stage Non-small Cell Lung Cancer

EP07.02. Prospective Study of Hypofractionated Proton Therapy for Inoperable Early Stage Non-small Cell Lung Cancer - PDF(Abstract)

Back to course

Pdf Summary

In this study presented at the WCLC 2023 conference, the authors investigated the use of hypofractionated proton therapy (PBT) as a treatment option for early-stage non-small cell lung cancer (NSCLC) patients who were not suitable for surgery or stereotactic body radiotherapy (SBRT). The study included 27 adult patients with NSCLC who met certain inclusion criteria, such as inoperability and inappropriate location for SBRT. The primary endpoint was local control, and secondary endpoints included overall survival, quality of life, and toxicity.<br /><br />The results showed that hypofractionated PBT was a safe treatment option for inoperable NSCLC patients, particularly for those with smaller tumor volumes. The two-year local control rate was 73.5%, with a higher rate observed in patients with T1 tumors compared to T2-3 tumors. Large clinical target volume and heavy smoking history were associated with worse local control rates. Overall survival rate was 76.5%.<br /><br />There were two cases of grade 3 radiation-related toxicities, including radiation pneumonitis in a patient with underlying idiopathic pulmonary fibrosis (IPF) and dermatitis in another patient. The authors also evaluated quality of life using the EORTC QLQ-C30 questionnaire and found that the global score did not significantly change after PBT. However, the dyspnea score increased at 4 months after PBT and remained consistent until 13 months.<br /><br />In conclusion, hypofractionated PBT appeared to be a safe treatment choice for inoperable NSCLC patients, particularly those with smaller tumor volumes. However, further improvements are needed to enhance local control, especially in larger-sized tumors. This study highlights the potential of proton therapy as an effective and well-tolerated treatment option for early-stage NSCLC patients.

Asset Subtitle

Kyungmi Yang

Meta Tag

Speaker Kyungmi Yang

Topic Early-Stage NSCLC: New Technology & Innovations

Keywords

hypofractionated proton therapy

non-small cell lung cancer

NSCLC

surgery

stereotactic body radiotherapy

inoperable patients

local control

overall survival

quality of life

toxicity